Clinical Trials Logo

Sarcopenia clinical trials

View clinical trials related to Sarcopenia.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06398704 Recruiting - Clinical trials for Geriatric Individuals

Investigation of the Effects of Sarcopenia and Dynapenia in Geriatric Individuals

Start date: April 15, 2024
Phase:
Study type: Observational

The aim of our study is to examine the effects of sarcopenia and dynapenia on inspiratory muscle strength and cardiorespiratory fitness in geriatric individuals.

NCT ID: NCT06394648 Recruiting - Clinical trials for Geriatric Individuals

Investigation of Sarcopenia and Physical Fitness Levels of Geriatric Individuals Living in Nursing Homes and at Home

Start date: April 5, 2024
Phase:
Study type: Observational

To examine the sarcopenia and physical fitness levels of geriatric individuals living in nursing homes and at home. Considering these aims, our working hypotheses are; H1: There is a difference in sarcopenia level between geriatric individuals living in a nursing home and at home. H2: There is a difference in dynapenia levels between geriatric individuals living in a nursing home and at home. H3: There is a difference in physical fitness between geriatric individuals living in a nursing home and at home.

NCT ID: NCT06393244 Recruiting - Sarcopenia Clinical Trials

A Theory-based Home-based Multi-component Exercise Training Among Older Adults With Type 2 Diabetes Mellitus

Start date: March 15, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn if a theory-based home-based multi-component exercise training works to prevent sarcopenia in older adults with type 2 diabetes mellitus. It will also learn about the safety of the theory-based home-based multi-component exercise training. The main questions it aims to answer are: - Whether a 12-week theory-based home-based MCE program is effective in decreasing the risk of developing sarcopenia, as well as improving physical activity, glycaemic control, muscle mass, muscle strength, physical performance, cognitive function, depressive mood, and quality of life among the Chinese community-dwelling older patients with T2DM. - What are the underlying mechanisms of the exercise intervention. Researchers will compare the MCE program to a waiting list control group to see if the MCE program works to prevent sarcopenia. Participants will: · Take a MCE program or a waiting list for 6 months

NCT ID: NCT06380777 Recruiting - Sarcopenia Clinical Trials

Establishment and Application of Digital Diagnosis and Treatment System for Sarcopenia

Start date: September 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to establish a digital diagnosis and treatment system for sarcopenia, integrating research outcomes into a unified approach encompassing a digital vaccine (early warning screening model), digital drug (intervention model associated with pathogenesis), and digital rehabilitation (preventive system combining early warning and treatment). This aims to create a digital visual tertiary prevention network for sarcopenia. Research aims: Evaluate the effectiveness of the digital vaccine through a cross-sectional epidemiological survey. Establish a specialized cohort for sarcopenia through a longitudinal investigation, implementing the digital drug and digital rehabilitation interventions. Participants will: Engage in screening and assessment based on inclusion and exclusion criteria. Be monitored longitudinally, with tailored interventions for those with muscle atrophy and regular follow-ups for at-risk individuals. Key outcomes will focus on sarcopenia indicators, serum biomarkers, and clinical endpoints such as fracture rates, weakness classification, and quality of life.

NCT ID: NCT06378788 Recruiting - Fibromyalgia Clinical Trials

Muscle Architecture and Muscle Strength in Fibromyalgia

Start date: February 1, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to determine whether there is decrease in muscle mass and muscle strength in Fibromyalgia Syndrome (FMS) patients in comparison to controls. And to determine whether these parameters are correlated with clinical ones. Briefly the main questions investigators aims to answer are: - Is there a significant difference in muscle morphology between FMS and controls? - Is there a significant difference in muscle strength between FMS and controls? - Is there a relationship between muscle thickness and pennation angle of the Quadriceps, gastrocnemius medialis, gastrocnemius lateralis and Tibialis anterior muscles and disease activity, pain and functionality? - Is there a correlation between muscle strength in FMS and disease activity, pain and functionality?

NCT ID: NCT06377254 Recruiting - Metabolic Syndrome Clinical Trials

Multi-organ Responses to CHronic Physical Activity and INactivity

CHAIN
Start date: March 12, 2024
Phase: N/A
Study type: Interventional

Life expectancy has been increasing for the last 150 years, but the maintenance of health has not kept pace with increased lifespan, and on average, UK adults spend the last decade of life in poor-health, with major consequences for society and the individual. Persistent physical inactivity is thought to be a key contributing factor to the risk of poor health and functional decline occurring in middle-aged and older adults. It is therefore concerning that most middle-aged adults spend >8hrs/day being sedentary, with average step count of 3000-4000 steps/day. To be able to holistically assess the effectiveness of future strategies to address age-related decline in health, and devise public health messages to help individuals reach older age in better health, it is essential that the complex physiological effects that activity and inactivity have across biological systems are characterised. The goal of this intervention study is to compare the impact of physical activity and inactivity on body functioning. Twenty moderately active participants will decrease their physical activity for six months to match the average amount carried out by middle-aged people in the UK. They will then undertake 3-months of reconditioning training to restore their fitness. In addition, twenty sedentary participants will increase their physical activity to UK recommended levels for six months. Before and at points during the intervention period, participants will be asked to make some measurements at home and attend the University of Nottingham to have multiple assessments made. These include; - fitness, muscle strength and function tests, - completion of questionnaires and computer-based brain puzzles - having muscle and fat tissue biopsies and blood samples taken. - The study also involves having MRI scans. This 5-year study will commence in January 2024, with participant recruitment starting in March 2024 and finishing in May 2027.

NCT ID: NCT06376266 Recruiting - Sarcopenia Clinical Trials

Assessment of the Intervention Effectiveness of Branched-chain Amino Acids(BCAA) Combined With Medium-chain Fatty Acid(MCFA) Products in Sarcopenia Among Middle-aged and Elderly Individuals

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

Taiwan entered an aging society in 2018 and is expected to transition into a super-aged society by 2025. With the increasing elderly population, age-related diseases pose urgent challenges to modern society. According to the Ministry of Health and Welfare's National Health Statistics in 2018, the prevalence of sarcopenia in Taiwan among individuals aged 65 and older is 23.6% for males and 18.6% for females. Sarcopenia, characterized by the loss of skeletal muscle mass due to aging, coupled with decreased muscle strength and/or reduced physical performance, poses a significant risk for disability, decreased quality of life, and increased mortality. Existing research indicates that appropriate nutrition and exercise can slow the onset of sarcopenia and even increase muscle mass to reverse its effects. This study is an interventional clinical trial recruiting middle-aged and elderly patients with sarcopenia or pre-sarcopenia. The intervention involves a combination of branched-chain amino acids and medium-chain triglyceride products, and the study aims to assess the effectiveness of this intervention for sarcopenia in middle-aged and elderly individuals.

NCT ID: NCT06363253 Recruiting - Obesity Clinical Trials

Pilot Study of the Human Metagenome in Metabolic Diseases

Start date: August 14, 2023
Phase:
Study type: Observational

This is a cohort study to understand the role of the human metagenome, and associated metabolites, in health and in various diseased states, in particular obesity as well as sarcopenia. Recruited participants will have their fecal, salivary, urine, serum, and in certain instances, mucosal samples taken, for metagenomic sequencing and metabolite testing. We hope to uncover various differences and signatures in the metagenome and metabolome in various diseased states, with potential future therapeutic applications in personalised medicine.

NCT ID: NCT06327594 Recruiting - Lung Cancer Clinical Trials

Assessment System of Sarcopenia in Lung Cancer Patients

Start date: November 1, 2023
Phase:
Study type: Observational

1. To explore the diagnostic value of musculoskeletal cross-modal imaging assessment system of ultrasound combined with abdominal CT/MRI for sarcopenia in patients with lung cancer. 2. To explore the value of musculoskeletal cross-modal imaging assessment system of ultrasound combined with abdominal CT/MRI in evaluating the prognosis and the effect of nutritional support in patients with lung cancer during perioperative period. 3. To explore the value of musculoskeletal cross-modal imaging assessment system of ultrasound combined with abdominal CT/MRI in evaluating the long-term prognosis of patients with lung cancer.

NCT ID: NCT06326086 Recruiting - Sarcopenia Clinical Trials

Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.

Start date: August 1, 2022
Phase:
Study type: Observational

Lung cancer is a common disease leading to 18 % of cancer deaths worldwide. Despite various improvement in treatment, there still remains low 5-year survival rate of 10-20 % in advanced lung cancer patients. Skeletal muscle mass and physical performance have been shown to effect overall survival and prognosis in lung cancer. This research focuses on effects of different treatment of lung cancer such as chemotherapy, targeted therapy and immunotherapy on skeletal muscle mass and physical performance.